With the business of analyzing and compiling the data of our 737 tracked hedge funds’ latest 13F filings behind us, we’re ready to start sharing some of the findings from ...
Keep Reading →
February 19 - Hedge Fund Analysis, Hedge Funds, News
Lance Helfert and Paul Orfalea’s West Coast Asset Management has left its equity portfolio relatively unchanged since last quarter, except for one big change.
Keep Reading →
October 15 - Hedge Funds, News
Ken Fisher’s Fisher Asset Management filed a few weeks ago its Form 13F for the second quarter of 2014.
Keep Reading →
August 19 - Hedge Funds, News
AQR Capital Management, managed by Cliff Asness, recently published its 13F filing with the U.S. Securities and Exchange Commission for the second quarter of 2014.
Keep Reading →
August 18 - Hedge Funds, News
In addition to providing energy products and services, BP plc (ADR) (NYSE:BP) holds a diversified equity portfolio, with a market value of more than $2.26 billion, which includes...
Keep Reading →
August 4 - Hedge Funds, Tech
Thomas Bailard is the co-founder and current manager of Bailard Inc. Located in California, Bailard uses quantitative and fundamental analyses to choose its investments.
Keep Reading →
August 1 - Hedge Funds, News
Drug major Johnson & Johnson (NYSE:JNJ) Chairman of the Board, Chief Executive Officer Alex Gorsky in a wide ranging interview with Carol Massar of Bloomberg TV on its "Bloomberg...
Keep Reading →
July 16 - News
In "Squawk on the Street" on CNBC, the co-anchor of the show Jim Cramer, comments on the Q2 earnings of Johnson & Johnson (NYSE:JNJ), which beats analysts expectations, and the...
Keep Reading →
July 15 - News
CNBC's Meg Tirrell reported on the popular “Squawk Box” program that patients suffering from Alzheimer disease in U.S and across the globe are assuming epidemic proportions...
Keep Reading →
July 11 - News
Last week, Ray Dalio’s Bridgewater Associates, one of the world’s largest hedge funds, with $161.9 billion in Assets Under Management, disclosed its long equity positions ...
Keep Reading →
May 20 - Hedge Funds, News
Billionaire Ken Fisher's Fisher Asset Management has recently revealed its equity portfolio as at the end of the first quarter of 2014.
Keep Reading →
April 24 - Hedge Fund Analysis, Hedge Funds, News
Stan Druckenmiller is a billionaire, and was the long-time manager of Duquesne Capital. Now, he oversees a family office, but his investing strategy is mostly the same.
Keep Reading →
February 24 - Hedge Funds, News
A few weeks ago, Lance Helfert and Paul Orfalea’s West Coast Asset Management filed its 13F Form at the U.S.
Keep Reading →
February 19 - Hedge Funds, News
In the latest 13F, Renaissance Technologies, previously managed by Jim Simons, revealed its holding for the fourth quarter of 2013.
Keep Reading →
February 14 - Hedge Funds, News
In the current round of 13F filings, hedge funds and other institutional investors are disclosing their equity portfolios as held at the end of the last year.
Keep Reading →
January 17 - Hedge Funds, News
All three companies have survived and thrived through two world wars, the Great Depression, countless financial panics and periods of booms and busts...
Keep Reading →
November 4 - News
How does George Soros invest? Opinions of George Soros vary depending on whom you ask, but there’s no arguing against the Hungarian-American hedge fund manager’s investing...
Keep Reading →
October 4 - Hedge Funds
Great dividend paying stocks with low debt ratios originally published at long-term-investments.blogspot.com.
Keep Reading →
September 20 - Dividend Stocks, News
When Obamacare was signed into law, medical device makers as a whole weren't happy campers. After all, the health reform legislation introduced an unwelcome 2.3% excise tax.
Keep Reading →
September 20 - News
It's arguably health care's biggest name.
Keep Reading →
September 19 - News
There is perhaps nothing scarier than a cancer diagnosis.
Keep Reading →
September 17 - News
Every so often, The Walt Disney Company (NYSE:DIS) faces an uncomfortable dilemma.
Keep Reading →
September 17 - Dividend Stocks, News
The small patient pool for medullary thyroid cancer, or MTC, isn't going to move the needle for a large pharmaceutical company. But Exelixis, Inc.
Keep Reading →
September 17 - News
Investing certainly means different things to different people.
Keep Reading →
September 16 - Dividend Stocks, News, Retirement
Heart disease is the leading cause of death in the United States. In 2010, according to data from the Centers for Disease Control and Prevention, 597,689 people in the U.S.
Keep Reading →
September 16 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
September 14 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
September 13 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
September 13 - Dividend Stocks, News
While Foolish readers know all too well that a good turnaround story can drive excellent shareholders, sometimes discretion is the better part of valor and it makes more sense...
Keep Reading →
September 13 - News
In a couple of years, Amgen, Inc. (NASDAQ:AMGN) will have to face the music when the patent for its $4 billion a year drug, Neulasta, expires in the U.S. and Europe.
Keep Reading →
September 12 - News
It hasn't been a fun month to be an investor in clinical-stage biotech ChemoCentryx Inc (NASDAQ:CCXI).
Keep Reading →
September 11 - News
Johnson & Johnson (NYSE:JNJ) recently announced a recall of around 200,000 bottles of Motrin Infants' Drops Original Berry Flavor.
Keep Reading →
September 11 - News
The Cooper Companies, Inc. (NYSE:COO), or more formally "The Cooper Companies" is a sort of odd duck in the med-tech world.
Keep Reading →
September 10 - News
Great results from a phase 3 study of soluble ferric pyrophosphate, or SFP, served as the catalyst. Rockwell Medical Inc (NASDAQ:RMTI) announced that the iron replacement therapy...
Keep Reading →
September 10 - News
The past year has been extremely volatile for Intuitive Surgical, Inc. (NASDAQ:ISRG), a stock once beloved by Wall Street and investors for its habit of producing strong growth...
Keep Reading →
September 10 - News
Several years ago, Johnson & Johnson (NYSE:JNJ) realized it had a problem with its drug business.
Keep Reading →
September 9 - News
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
September 9 - News
The Dogs of the Dow strategy involve investing equal amounts into the 10 highest-yielding dividend stocks on the Dow Jones Industrial Average 2 Minute (INDEXDJX:.DJI).
Keep Reading →
September 6 - News
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Keep Reading →
September 5 - News
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Keep Reading →
September 5 - News
Pharmaceutical firms spend a lot of money to influence physicians to prescribe their products.
Keep Reading →
September 5 - News
The Cooper Companies, Inc.
Keep Reading →
September 4 - News
Over the past decade, the Food and Drug Administration has taken multiple steps to improve the process by which drugs are developed and eventually brought to market.
Keep Reading →
September 4 - News
The stocks that have richly rewarded their shareholders for several decades have some qualities in common.
Keep Reading →
September 4 - News
In the summer of 2011, I set out to show Fools, step-by-step, how I would be building my own retirement portfolio.
Keep Reading →
September 4 - News
It should come as no surprise to anyone that the Food and Drug Administration granted a priority review for Pharmacyclics, Inc.
Keep Reading →
September 3 - News
There is plenty of geopolitical and economic uncertainty present in the middle term.
Keep Reading →
September 3 - News